Latest Carboplatin Stories
COLUMBIA, Md., Sept.
CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
CALGARY, July 19 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer (NSCLC).
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer.
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival.
CALGARY, June 7 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a poster presentation covering updated results of its Phase I/II U.K.
The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma.
The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone.
CALGARY, June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
- An interdisciplinary study of social injustice.